Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Corvus Pharmaceuticals Inc (CRVS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/22/2025: CRVS (4-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Analysis of Past Performance
Type Stock | Historic Profit 728.16% | Avg. Invested days 34 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 04/22/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 226.89M USD | Price to earnings Ratio - | 1Y Target Price 15 |
Price to earnings Ratio - | 1Y Target Price 15 | ||
Volume (30-day avg) 796465 | Beta 0.7 | 52 Weeks Range 1.41 - 10.00 | Updated Date 04/23/2025 |
52 Weeks Range 1.41 - 10.00 | Updated Date 04/23/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.02 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -30.09% | Return on Equity (TTM) -174.85% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 176050200 | Price to Sales(TTM) - |
Enterprise Value 176050200 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.36 | Shares Outstanding 68135800 | Shares Floating 52153182 |
Shares Outstanding 68135800 | Shares Floating 52153182 | ||
Percent Insiders 3.25 | Percent Institutions 55.45 |
Analyst Ratings
Rating 4.83 | Target Price 15 | Buy 1 | Strong Buy 5 |
Buy 1 | Strong Buy 5 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Corvus Pharmaceuticals Inc
Company Overview
History and Background
Corvus Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies. Founded in 2014, it has progressed multiple programs targeting the tumor microenvironment and immune cell activation. It aims to develop small molecules that activate the immune system to fight cancer.
Core Business Areas
- Immuno-Oncology: Development of novel therapies that harness the immune system to fight cancer. Focus on small molecule agents targeting the adenosine pathway and other immune checkpoints.
Leadership and Structure
The company is led by Richard A. Miller, M.D., President and Chief Executive Officer. The organizational structure consists of research and development, clinical operations, and corporate functions.
Top Products and Market Share
Key Offerings
- CPI-818: An oral small molecule that selectively inhibits ITK (interleukin-2-inducible T-cell kinase), currently in clinical trials for various T-cell lymphomas and autoimmune diseases. Market share data not publicly available. Competitors include companies developing other ITK inhibitors and treatments for T-cell lymphomas, like Seagen (SGEN) and Kyowa Kirin (4151.JP).
- Soquelitin (CPI-444): A small molecule adenosine A2A receptor antagonist. Adenosine is produced in tumors and disables immune cells. Soquelitin is designed to block the receptor, allowing the immune cells to attack the tumor. Competitors include companies developing A2A receptor antagonists, such as Arcus Biosciences (RCUS).
Market Dynamics
Industry Overview
The immuno-oncology market is experiencing significant growth, driven by the increasing prevalence of cancer and the effectiveness of immune-based therapies. Key trends include combination therapies, personalized medicine, and the development of novel targets.
Positioning
Corvus is positioning itself as an innovator in immuno-oncology, focusing on novel targets and small molecule approaches. Its competitive advantage lies in its proprietary drug discovery platform and clinical expertise. Its small molecule approach allows it to get where other biologics can't.
Total Addressable Market (TAM)
The global immuno-oncology market is projected to reach hundreds of billions of dollars. Corvus aims to capture a portion of this market by developing targeted therapies for specific cancer types. The TAM that Corvus is targeting with CPI-818 and CPI-444 is several billion dollars, however, being a small biotech firm it's success will be dependant on partnerships and good data.
Upturn SWOT Analysis
Strengths
- Novel immuno-oncology pipeline
- Experienced management team
- Proprietary drug discovery platform
- Early clinical data showing promise
Weaknesses
- Limited financial resources
- Dependence on clinical trial success
- Competition from larger pharmaceutical companies
- No currently marketed products
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of clinical trial programs
- Potential for breakthrough therapies
- Acquisition by a larger company
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from new therapies
- Economic downturn affecting investment in biotechnology
Competitors and Market Share
Key Competitors
- RCUS
- MRTX
- NKTR
Competitive Landscape
Corvus faces competition from established pharmaceutical companies and other biotechnology firms developing immuno-oncology therapies. Its small molecule approach provides a potential advantage, but it needs to demonstrate clinical efficacy and secure partnerships to compete effectively. These are just rough estimations based on the market cap of the firms.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Corvus has not had revenue growth but has been increasing its clinical trials and programs. This leads to further growth to increase the pipeline.
Future Projections: Future growth will be contingent on clinical trial successes and potential partnerships or acquisitions. Analyst estimates vary widely depending on the perceived likelihood of success.
Recent Initiatives: Advancement of CPI-818 and CPI-444 clinical trials, exploration of new immuno-oncology targets, and building strategic partnerships.
Summary
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company with a promising pipeline of immuno-oncology therapies. Its strengths lie in its innovative approach and experienced team. However, it faces challenges due to limited financial resources and competition from larger companies. Success hinges on clinical trial results and strategic partnerships for future growth.
Similar Companies
AGEN
Agenus Inc
AGEN
Agenus Inc
NKTR
Nektar Therapeutics
NKTR
Nektar Therapeutics
RCUS
Arcus Biosciences Inc
RCUS
Arcus Biosciences Inc
Sources and Disclaimers
Data Sources:
- Corvus Pharmaceuticals Inc. website
- SEC filings
- Analyst reports
- Company press releases
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share data is approximate based on publicly available information and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Corvus Pharmaceuticals Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2016-03-23 | Co-Founder, President, CEO & Chairman of the Board Dr. Richard A. Miller M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 31 | Website https://www.corvuspharma.com |
Full time employees 31 | Website https://www.corvuspharma.com | ||
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell atopic dermatitis, asthma, psoriasis, and fibrotic diseases. It also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer. It has a license agreement with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in South San Francisco, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.